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Introduction
Rheumatoid arthritis (RA) is characterized by persistent 
inflammation in joints that leads to damage in the sur-
rounding cartilage and bone. Patients with RA have been 
shown to be at increased risk for hospitalized infectious 
events (HIEs) compared to the general population [1, 2], 
and the risk increases with more severe disease [3]. A ret-
rospective longitudinal study showed that the rate of infec-
tions requiring medical care among patients diagnosed with 
RA (19.6 cases per 100 person-years) was greater than the 
rate for patients without an RA diagnosis (12.9 cases per 
100 person-years) [1]. In a retrospective study of HIEs, 
the adjusted hazard ratio (HR) for infection was 2.03 [95% 
confidence interval (CI) 1.93–2.13] for patients with RA vs 
those without RA [2]. It is not clear if this increased risk is 
due to dysregulation of the immune system characteristic of 
inflammatory diseases.
Current therapies for the treatment of RA include many 
drugs that have immunosuppressive properties, such as 
tumor necrosis factor inhibitor (TNFi) medications and 
glucocorticoids (GCs). A prospective observational study 
found that patients with RA treated with a TNFi had 20% 
greater risk of serious infection (defined as requiring intra-
venous antibiotics or hospitalization or resulting in death) 
compared to patients with RA treated with nonbiologic dis-
ease-modifying antirheumatic drugs (DMARDs) (adjusted 
HR 1.2; 95% CI 1.1–1.5) [4]. Notably, serious infections 
were infrequent in both groups, with rates of 42 and 32 
serious infections per 1000 person-years in TNFi-treated 
and nonbiologic DMARD-treated patients, respectively.
Abstract The objective of this study was to evaluate the 
impact of oral glucocorticoid (GC) dose on rates of hospi-
talized infectious events (HIEs) among RA patients newly 
exposed to tumor necrosis factor inhibitor (TNFi) therapy. 
This retrospective cohort study used data from the Mar-
ketScan claims database. Incident and prevalent adult RA 
patients newly exposed to TNFi therapy were identified and 
assigned to three cohorts: no GC, low-dose GC (≤7.5 mg), 
and high-dose GC (>7.5  mg); patients could contribute 
exposure time to multiple cohorts if they changed dose 
or discontinued GC. The primary outcome was estimated 
incidence rate (IR) of HIEs per 100 patient-years of GC 
exposure. A total of 40,933 eligible patients were identified 
(mean age 53.0 years; 77.4% female). HIE risk increased 
with increasing GC dose: the IR [95% confidence inter-
val (CI)] was 3.9 (3.63–4.13) for no GC; 6.4 (5.68–7.16) 
for low-dose GC; and 13.3 (11.9–15.5) for high-dose GC. 
Adjusted rate ratios (95% CI) were 1.4 (1.21–1.60) for low-
dose vs no GC; 2.8 (2.32–3.34) for high-dose vs no GC, 
and 2.0 (1.66–2.45) for high-dose vs low-dose GC. The risk 
of HIEs increased with increasing age. HIE risk did not 
increase with longer exposure to GCs. Oral GCs, regardless 
of dose, significantly increased the risk of HIEs among RA 
patients newly initiating TNFi therapy. Steroid dosing must 
be considered when assessing infection risk in treatment 
decisions for RA patients.
Rheumatology
INTERNATIONAL 
 * Neil A. Accortt 
 naccortt@amgen.com
1 DOCS Global, Inc., North Wales, PA, USA




Studies have suggested that oral GCs further increase the 
risk of HIEs among patients with RA. Although definitions 
of low and high dose vary between studies, exposure to 
low-dose GCs has been shown to increase the risk of HIEs, 
and exposure to high-dose GCs further increased the risk 
of serious infection and HIEs [5–9]. The purpose of this 
study was to better understand the impact of concomitant 
use of GCs among RA patients who were newly exposed 
to TNFi therapy. We estimated the incidence rates (IRs) of 
HIEs based on exposure to TNFi medications (both collec-
tively and individually) and to exposure to various levels of 
GCs. The hypothesis to be tested was that the rate of HIEs 
is higher among patients with RA on TNFi medications 
exposed to low-dose oral GCs as compared to patients on 
TNFi medications who are not exposed to oral GCs.
Materials and methods
Study design and data source
This was a retrospective cohort study that utilized the Mar-
ketScan Commercial and Medicare supplemental claims 
database from January 1, 2005 through June 30, 2014. The 
commercial database contains the inpatient, outpatient, 
and outpatient prescription drug experience of ~40 million 
employees and their dependents, who are covered under a 
variety of fee-for-service and managed care health plans. 
The Medicare database contains the healthcare experience 
of ~3  million retirees with Medicare supplemental insur-
ance paid for by employers. Both databases contain detailed 
cost, use, and outcomes data for inpatient and outpatient 
healthcare services. The medical claims are linked to out-
patient prescription drug claims and person-level enroll-
ment data through the use of unique enrollee identifiers.
The index date was the first exposure to TNFi therapy 
(adalimumab, certolizumab pegol, etanercept, golimumab, 
or infliximab). The baseline period was the 6 months 
preceding the index date, which was used to ensure that 
patients were TNFi-naïve. The follow-up period began on 
the index date for each patient and lasted up to 2  years. 
Follow-up ended on the earliest date of: disenrollment from 
MarketScan, HIE outcome diagnosis date, discontinuation 
of TNFi therapy, end of study (June 30, 2014), or 2 years 
after index date.
TNFi exposure was based on time from index date until 
the patient discontinued use of TNFi medication. Patients 
were permitted to switch TNFi medication if there was no 
interruption in TNFi use without truncating the time of 
follow-up. Exposure to oral GCs was assessed during the 
follow-up period and was categorized as: no exposure, 
very low dose (≤5.0 mg), low dose (≤7.5 mg), high dose 
(>7.5  mg), and very high dose (>20  mg). A sensitivity 
analysis of a dose ≥10 mg based on categories of low-dose 
and high-dose GCs as defined by the American College of 
Rheumatology (ACR) [10] was also performed. All ster-
oid claims were converted to a 5 mg prednisone equivalent 
dose. Patients could have multiple oral GC exposures and 
could contribute time to different GC exposure categories, 
including the ‘no exposure’ category when they were off 
GCs. For example, a patient could have had several claims 
for varying low or high GC doses over the follow-up time, 
as well as intervals without GC claims. Each GC exposure 
was then allocated to the appropriate GC dose cohort and 
the time that patients were not receiving any GC was allo-
cated to the no GC cohort. Cumulative episodic exposures 
for each dose cohort were measured. To accommodate the 
time required for drug clearance, the exposure time for 
high-dose exposures was extended an additional 3 days. 
If the patient transitioned directly from a high-dose to a 
low-dose GC, the low-dose exposure time was delayed by 
3 days and the initial 3 days after the dose decrease were 
attributed to the high-dose GC. Exposure to other RA med-
ications, such as nonbiologic DMARDs, was collected only 
during the baseline period.
Patients
Eligible patients were aged ≥18 years and had a confirmed 
diagnosis of RA [International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) code 
714.0] defined by one inpatient or one outpatient diag-
nostic claim accompanied by ≥1 prescription for a TNFi 
medication within 30 days prior to and ≤365 days after an 
RA claim date. Patients were required to have ≥12 months 
of continuous enrollment with pharmacy coverage, which 
included the 6-month baseline period and at least 6 months 
of follow-up. Patients were excluded if they had a con-
firmed diagnosis of psoriasis, psoriatic arthritis, ankylosing 
spondylitis, and/or inflammatory bowel disease (other indi-
cations for TNFi medications), a confirmed diagnosis of 
HIV/AIDS, any malignancy (excluding nonmelanoma skin 
cancer), receipt of an organ transplant before index date, 
exposure to a TNFi medication during the baseline period, 
and any inpatient HIE diagnostic claim with one overnight 
hospitalization stay in which the HIE diagnosis was the pri-
mary or secondary reason for hospitalization during the 90 
days preceding and including the index date.
Study outcomes
The rate of incident HIEs was estimated for each oral GC 
exposure group, for collective TNFi exposures, and for 
individual TNFi medication exposures. Rate ratios compar-
ing the incidence rates of patients with low- and high-dose 




Incidence rates (IRs) of HIEs and 95% CIs were calculated 
per 100 patient-years. Univariate and multivariable Pois-
son regression models were used to assess the association 
between TNFi exposure, oral GC exposure, demograph-
ics, baseline comorbidities, concomitant medications, and 
HIEs. Covariates with P < 0.20 in univariate models were 
included in the initial multivariable model. Further evalu-
ation was conducted to produce the most parsimonious 
model. Baseline demographics and clinical characteristics 
were based on GC category on the index date; categories 
were mutually exclusive at baseline.
Results
Patients
A total of 40,933 eligible patients were identified in the 
database. At baseline, the distribution was as follows: 
28,867 patients (70.5%) on no GC, 9011 (22.0%) on low-
dose GC, and 3055 (7.5%) on high-dose GC. Within the 
low-dose GC cohort, a subset of 8632 were on very low-
dose GC and within the high-dose GC cohort, 131 were on 
very high dose GC. Most patients were women (77.4%), 
and the mean age was 53.0 [standard deviation (SD) 12.6] 
years (Table 1).
IRs of HIEs
HIE IRs were similar for all patients receiving low-
dose GC (≤7.5 mg) and the subset of patients with very 
Table 1  Baseline demographic and clinical characteristics
Dose cohorts for demographic and clinical descriptions are based on status at index date and are mutually exclusive
COPD chronic obstructive pulmonary disease, DMARD disease-modifying antirheumatic drug, GC glucocorticoid, HIEs hospitalized infectious 
events
a Very low dose GC cohort is a subset of the low-dose GC cohort
b Very high dose GC cohort is a subset of the high-dose GC cohort
No GC
N = 28,867









Very high dose  GCb
(>20.0 mg)
N = 131
Age, mean years 52.5 54.2 54.3 53.4 51.6
Age category, n (%)
 <65 years 25,606 (88.7) 7345 (85.1) 7642 (84.8) 2662 (87.1) 117 (89.3)
 ≥65 years 3261 (11.3) 1287 (14.9) 1369 (15.2) 393 (12.9) 14 (10.7)
Sex, n female (%) 22,818 (79.0) 6459 (74.8) 6731 (74.7) 2130 (69.7) 91 (69.5)
Select comorbidities, n (%)
 Hypertension 2,722 (9.4) 938 (10.9) 981 (10.9) 370 (12.1) 14 (10.7)
 Diabetes 1891 (6.6) 475 (5.5) 496 (5.5) 204 (6.7) 9 (6.9)
 Congestive heart failure 574 (2.0) 223 (2.6) 241 (2.7) 105 (3.4) 5 (3.8)
 Asthma 435 (1.5) 113 (1.3) 122 (1.4) 71 (2.3) 4 (3.1)
 COPD 375 (1.3) 178 (2.1) 191 (2.1) 80 (2.6) 7 (5.3)
 Renal disease 277 (1.0) 80 (0.9) 87 (1.0) 60 (2.0) 4 (3.1)
 Peripheral vascular disease 262 (0.9) 97 (1.1) 103 (1.1) 60 (2.0) 5 (3.8)
Exposure to injectable GC, n (%) 9398 (32.6) 3025 (35.0) 3152 (35.0) 1214 (39.7) 49 (37.4)
Exposure to oral GC, n (%) 12,240 (42.4) 8,475 (98.2) 8,851 (98.2) 3,021 (98.9) 129 (98.5)
Exposure to nonbiologic DMARD, n (%) 22,097 (76.5) 7372 (85.4) 7701 (85.5) 2586 (84.6) 103 (78.6)
Exposure to biologic DMARD, n (%)
 Adalimumab 9636 (33.4) 3086 (35.8) 3213 (35.7) 1066 (34.9) 48 (36.6)
 Certolizumab pegol 776 (2.7) 213 (2.5) 224 (2.5) 71 (2.3) 3 (2.3)
 Etanercept 13,052 (45.2) 3842 (44.5) 4009 (44.5) 1366 (44.7) 55 (42.0)
 Golimumab 781 (2.7) 212 (2.5) 224 (2.5) 75 (2.5) 5 (3.8)
 Infliximab 4615 (16.0) 1279 (14.8) 1341 (14.9) 477 (15.6) 20 (15.3)
HIEs, n (%) 276 (1.0) 111 (1.3) 116 (1.3) 53 (1.7) 1 (0.8)
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low-dose GC (≤5.0  mg), and increased with increasing 
GC dose (Table  2). IRs were higher for patients ≥65 
years of age in the no GC cohort and across all GC dose 
cohorts. A post hoc analysis of HIEs was conducted 
for the subset of patients receiving a very low GC dose 
(<5  mg) compared with patients who received exactly 
5 mg. These results were consistent with the trend show-
ing decreased incidence of HIEs with decreasing dose: 
the IR per 100 patient-years (95% CI) was 5.7 (4.23–7.43) 
for patients who received <5 mg GC, and 6.7 (5.74–7.48) 
for patients who received exactly 5 mg GC. A sensitivity 
analysis using a cut-off of >10 mg based on the ACR def-
inition of high dose was also consistent with the GC dose 
relationship to HIEs: the IR per 100 patient-years (95% 
CI) was 26.4 (20.40–32.33) for patients who received 
>10 mg GC. For patients aged <65 years and ≥65 years, 
respectively, the IRs (95% CI) were 22.5 (16.36–28.57) 
and 43.4 (25.67–61.16) for GC >10  mg. There was a 
trend toward lower IRs with longer duration of GC expo-
sure across all GC dose cohorts (Table 3). IRs for HIEs 
were generally similar across TNFi medications for 
patients receiving no GC and low-dose GC, although inf-
liximab appeared to have the highest IRs for all GC dose 
cohorts (Fig.  1). For patients receiving high-dose GC, 
results were variable among the TNFi medications, pos-
sibly due to the relatively small number of patient-years 
of exposure for this GC dose cohort. The most common 
infections requiring hospitalization across all GC dose 
Table 2  Summary of IRs of HIEs stratified by age group
CI confidence interval, GC glucocorticoid, HIE hospitalized infectious event, IR incidence rate
a Very low dose GC cohort is a subset of the low-dose GC cohort
b Very high dose GC cohort is a subset of the high-dose GC cohort






Very high dose  GCb
(>20.0 mg)
All ages
 Total patient-years 23,654.2 4375.4 4603.1 1211.6 45.0
 IR per 100 patient-years 3.9 6.4 6.4 13.3 24.5
  (95% CI) (3.63–4.13) (5.65–7.17) (5.68–7.16) (11.32–15.51) (12.21–43.76)
Ages <65 years
 Total patient-years 20,085.2 3463.1 3634.0 995.2 35.8
 IR per 100 patient-years 3.2 4.7 4.7 11.7 22.3
  (95% CI) (2.91–3.40) (4.04–5.52) (4.00–5.44) (9.63–13.98) (9.64–43.98)
Ages ≥65 years
 Total patient-years 3,569.0 912.3 969.1 216.4 9.1
 IR per 100 patient-years 8.0 12.6 12.8 20.8 32.9
  (95% CI) (7.06–8.94) (10.41–15.13) (10.64–15.26) (15.17–27.83) (6.77–95.99)
Table 3  Summary of IRs of HIEs stratified by follow-up time
CI confidence interval, GC glucocorticoid, HIE hospitalized infectious event, IR incidence rate
1–14 days follow-up 15–29 days follow-up 30–59 days follow-up ≥60 daysfollow-up
No GC
 No. of HIE cases (total patient-years) 54 (1,494.2) 76 (1515.7) 122 (2694.5) 664 (17,949.8)
 IR per 100 patient-years (95% CI) 3.6 (2.71–4.72) 5.0 (3.95–6.28) 4.5 (3.76–5.41) 3.7 (3.42–3.99)
 Rate ratio (95% CI) Reference 1.4 (0.98–1.97) 1.3 (0.91–1.73) 1.0 (0.78–1.35)
Low-dose GC
 No. of HIE cases (Total patient-years) 42 (625) 34 (549.9) 62 (790.2) 156 (2,638.1)
 IR per 100 patient-years (95% CI) 6.7 (4.84–9.08) 6.2 (4.28–8.64) 7.9 (6.02–10.06) 5.9 (5.02–6.92)
 Rate ratio (95% CI) Reference 0.9 (0.59–1.45) 1.2 (0.79–1.73) 0.88 (0.63–1.24)
High-dose GC
 No. of HIE cases (total patient-years) 47 (356.5) 23 (230.3) 34 (246.0) 57 (378.8)
 IR per 100 patient-years (95% CI) 13.2 (9.69–17.53) 10.0 (6.33–14.99) 13.8 (9.57–19.32) 15.1 (11.4–19.5)
 Rate ratio (95% CI) Reference 0.8 (0.46–1.25) 1.1 (0.67–1.63) 1.1 (0.78–1.68)
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cohorts were pneumonia, cellulitis/abscess, and septice-
mia (Table 4).
Adjusted rate ratios for HIEs
After controlling for variables of baseline GC dose, age, 
use of injectable or oral GCs, use of nonbiologic DMARDs, 
comorbidities (diabetes, asthma, renal disease, congestive 
heart failure, hypertension, peripheral vascular disease, and 
chronic obstructive pulmonary disease (COPD); assessed 
individually), baseline HIEs, and exposure to TNFi medi-
cations, the adjusted rate ratio (95% CI) for low-dose GC 
vs no GC was 1.4 (1.19–1.58), for high-dose GC vs no GC 
was 2.8 (2.30–3.31), and for high-dose GC vs low-dose GC 
was 2.0 (1.65–2.44) (Table  5). These variables were also 
independent predictors of HIE risk for both low- and high-
dose GCs except for peripheral vascular disease, which was 
a predictor of HIE risk for only high-dose GCs. Infliximab 
was independently associated with a higher rate of infection 
among all steroid dose comparisons, while adalimumab 
was associated with a slight increase in the high-dose to no 
GC comparison.
Discussion
Rates of HIEs in this analysis of patients with RA were 
lowest for patients on no GC and increased with increas-
ing dose of oral GCs. In a similar analysis of RA patients, 
the overall rate of infections requiring hospitalization was 
9.6 cases per 100 person-years [1], compared with IRs of 
3.9, 6.4 and 13.3 per 100 patient-years for patients on no 
GC, low-dose GC, and high-dose GC, respectively, in our 
study. Rates of HIEs were fairly similar across TNFi medi-
cations for each GC dose cohort; although patients on inf-
liximab had consistently higher rates of HIEs in each GC 
dose cohort. These results are consistent with an analysis 
of data from the US Veterans Administration, in which 
rates of hospitalizations for bacterial infections were simi-
lar between adalimumab, and etanercept, and higher for 
infliximab [7]. Results from that study also showed that 
patients receiving doses of prednisone >7.5  mg/day were 
at increased risk of infection [7]. Data from the Canadian 
BioTRAC registry showed that RA patients treated with 
infliximab receiving GCs at a dose >5 mg were 2.48 times 
more likely to develop an infection than patients with no 
GC exposure [11].
The trend of GC-dose-dependent increased rates of 
infection has been reported previously. Dixon et al. showed 
that increases in GC dose led to increases in relative risk 
for infection, with relative risks of 2.5, 3.0, and 4.3 for GC 
doses of 5, 10, and >20 mg, respectively [12]. RA therapies 
and treatment status (naïve or previously treated) were not 
reported, and the authors noted that adjustment for comor-
bidity and RA therapies led to estimates that were ~40% 
higher than the unadjusted estimates. Data from the Ger-





































































Fig. 1  Incidence rates of HIEs stratified by index TNFi medication. 
HIE incidence rates are shown for patients receiving TNFi medication 
exposed to no GC, low-dose GC, or high-dose GC. Error bars repre-
sent 95% CI. ADA adalimumab, CER certolizumab pegol, CI confi-
dence interval, ETN etanercept, GC glucocorticoid, GOL golimumab, 
HIE hospitalized infectious event, INF infliximab, TNFi tumor necro-
sis factor inhibitor
Table 4  Most common infections requiring hospitalization
HIEs hospitalized infectious events, GC glucocorticoid, HIEs hospitalized infectious events







dose GC (11 
HIEs)
Pneumonia (organism unspecified) 181 (19.8) 59 (21.2) 64 (21.8) 31 (19.3) 3 (27.3)
Cellulitis/abscess 101 (11.0) 31 (11.1) 31 (10.5) 16 (9.9) 1 (9.0)
Septicemia 92 (10.0) 37 (13.3) 38 (12.9) 19 (11.8) 1 (9.0)
Pleurisy 69 (7.5) 17 (6.1) 17 (5.8)
Disorders of urethra/urinary tract 63 (6.9) 18 (6.5) 22 (7.5) 10 (6.2) 1 (9.0)
 Rheumatol Int
1 3
(95% CI) of infections in patients receiving a very high 
GC dose (≥15 mg) or a high GC dose (7.5–14 mg) were 
4.7 (2.4–9.4) and 2.1 (1.4–3.2), respectively, compared to 
patients with no GC exposure [13].
The ACR defines low-dose and high-dose GCs as 
≤10  mg and >10  mg, respectively [10]. Based on this 
cut-off, we conducted a sensitivity analysis and found that 
the IR (95% CI) for HIEs was 26.4 (20.4–32.33) per 100 
patient-years for all patients receiving>10 mg and a nota-
ble 43.4 (25.67–61.16) for patients ≥65 years of age. These 
results are consistent with findings from a study that was 
designed to identify risk factors for serious infections in RA 
patients. In that study, patients receiving a dose >10  mg 
were 3.97 times more likely to develop a serious infection 
compared to patients on no GC, and that patients aged ≥80 
years were at higher risk for developing an infection than 
patients aged <80 years (HR 2.18; 95% CI 1.21–3.91) [14]. 
The high risk of infection needs to be considered when 
selecting a GC dose for elderly patients with RA.
Per the new ACR guidelines for the treatment of RA, 
combination therapy can be steroid sparing [10]. Our 
analysis showed that exposure to nonbiologic DMARDs 
during the baseline period was associated with a 20–30% 
reduction in HIE rate ratios. This finding could be due to 
better disease control with combination therapy or chan-
neling of patients at high risk of infections away from com-
bination therapy. Our analyses were not stratified by con-
comitant use of nonbiologic DMARD therapies throughout 
the follow-up period, and further research is required to 
address the impact of combination therapy on HIE rates.
Age was a strong predictor of HIE risk for both low 
and high GC doses. Additionally, comorbidities of dia-
betes, asthma, renal disease, congestive heart failure, 
hypertension, and COPD were strong predictors of HIE 
risk for low and high GC doses. Hypertension, peripheral 
vascular disease, and COPD were predictors of HIE risk 
for high-dose GC but not for low-dose GC. Among the 
individual TNFi treatments, infliximab was associated 
with a higher rate of infection at both the low- and high-
dose comparisons, consistent with other studies [8, 15]. 
Notably, the infliximab cohort was older than the other 
TNFi cohorts (data not shown), and a high proportion of 
patients ≥65 years of age may have also contributed to 
the higher HIE rate for infliximab. This observation may 
be due in part to healthcare coverage for elderly patients: 
infused drugs such as infliximab are covered by Medicare 
Table 5  Adjusted rate ratios for 
HIEs for no GC, low-dose GC, 
and high-dose GC
RR rate ratio, GC glucocorticoid, DMARD disease-modifying antirheumatic drug, COPD chronic obstruc-
tive pulmonary disease, CI confidence interval
*P ≤ 0.05
† P ≤ 0.001
‡ P ≤ 0.0001
Low-dose GC vs No 
GC




RR 95% CI RR 95% CI RR 95% CI
Crude rate ratios 1.7 1.45–1.88 3.4 2.90–4.06 2.2 1.78–2.61
Adjusted rate ratios 1.4‡ 1.19–1.58 2.8‡ 2.90–4.06 2.0‡ 1.65–2.44
Age (continuous) 1.0‡ 0.97–0.98 1.0‡ 0.97–0.98 1.0‡ 0.96–0.98
Exposure to injectable GC 1.3‡ 1.17–1.47 1.3‡ 1.16–1.48 1.3* 1.07–1.56
Exposure to oral GC 1.2* 1.09–1.42 1.2* 1.07–1.40 0.8 0.56–1.08
Exposure to nonbiologic DMARD 0.7‡ 0.64–0.86 0.8* 0.67–0.91 0.7* 0.53–0.86
Diabetes 1.5‡ 1.24–1.82 1.7‡ 1.37–2.01 1.1 0.82–1.58
Asthma 2.0‡ 1.42–2.73 1.8† 1.29–2.57 1.1 0.65–2.04
Renal disease 1.7* 1.21–2.41 1.7* 1.22–2.46 1.4 0.86–2.37
Congestive heart failure 1.4* 1.08–1.83 1.4* 1.08–1.88 1.3 0.88–1.94
Hypertension 1.4† 1.16–1.62 1.3* 1.07–1.52 1.5† 1.18–1.93
Peripheral vascular disease 1.2 0.82–1.81 1.4 0.97–2.14 0.5* 0.22–0.93
COPD 2.0‡ 1.53–2.73 2.0‡ 1.44–2.69 2.2‡ 1.49–3.34
HIE during baseline 1.8† 1.28–2.58 1.6* 1.11–2.44 2.0* 1.22–3.39
Etanercept Reference Reference Reference
Adalimumab 1.1 0.91–1.23 1.3* 1.07–1.47 1.1 0.84–1.36
Infliximab 1.6‡ 1.38–1.84 1.8‡ 1.50–2.05 1.6‡ 1.29–2.06
Golimumab 0.9 0.62–1.28 1.1 0.77–1.59 1.2 0.71–2.10
Certolizumab pegol 1.1 0.73–1.74 1.1 0.69–1.81 0.8 0.37–1.92
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Part B coverage whereas self-injected TNFi medications 
are not. Sample size was too small to allow for analyses 
by individual TNFi medications among those patients 
>65 years of age.
This study was unique in that it included the assessment 
of HIEs in patients newly initiating TNFi therapy, and also 
considered the duration of both TNFi and GC exposures 
and GC dose levels. A strength of the study was the amount 
of data available from the commercial claims database. 
The large patient population allowed for the evaluation of 
different dose levels and GC dose categories. The claims 
database also provides information on many variables 
(demographic, diagnostic, prescription claims for concur-
rent medications, etc.) that contributed to the analysis. The 
study also had some limitations. While underlying disease 
activity was not known, we did limit the analysis to patients 
who were newly initiating TNFi therapy and therefore 
expected to be comparable with relation to disease activ-
ity. Unmeasured confounding of disease severity is there-
fore a limitation of this study. TNFi exposure and oral GC 
dose levels were defined using administrative claims and 
pharmacy data, resulting in an inherent risk of misclassifi-
cation error. Prednisone tapering may have occurred; how-
ever, based on limitations of the dataset, we were unable to 
identify when this occurred. Outpatient prescription claims 
used to identify therapies only indicated that a prescription 
was filled, but provided no information on actual utilization 
of the medication by the patient. A patient might not sub-
mit a reimbursement claim for a pharmacy-filled GC pre-
scription, or might split doses to extend a prescription or 
to save cost; therefore, there is potential for misclassifica-
tion of oral GC exposure status. The sample size was quite 
small for some subset analyses, particularly in the high-
dose category, and the results of those analyses should be 
interpreted with caution.
In conclusion, doses of oral GCs as low as 5 mg were 
associated with an increased risk of infection in this cohort 
of RA patients. As with other subsets of the RA population, 
clinicians need to consider the steroid dose when evaluat-
ing the risk of infection among patients newly initiating 
TNFi therapies.
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